… patients according to different lines of gefitinib or erlotinib. The disparities of choices on gefitinib
or erlotinib (… In conclusion, selecting between erlotinib and gefitinib for treating NSLCL is …

… Although both gefitinib and erlotinib target the same EGFR kinase domain, it remains to be …
gefitinib and erlotinib provide the same treatment outcomes in advanced NSCLC patients. For …

… We examined 15 Japanese patients with NSCLC and CNS … -TKI treatment (250 mg daily
gefitinib or 150 mg daily erlotinib) … of the 15 patients received gefitinib and erlotinib treatment; …

… no difference in PFS between the erlotinib- and gefitinib-treated groups (11.7 vs. 14.5 …
study of matched Asian patients (121 pairs) with NSCLC (13). These patients were young (median …

… of erlotinib after failure of gefitinib treatment in patients with non-small-cell lung cancer (NSCLC).
Patients and methods: Patients … on gefitinib treatment were treated with erlotinib 150 mg/…

… The small molecule EGFR TKIs, gefitinib and erlotinib, have both demonstrated antitumor
activity as a single agent in the treatment of patients with advanced NSCLC. Recently, reported …

… We retrospectively reviewed the records of 467 NSCLC patients who had been treated with
gefitinib or erlotinib at Samsung Medical Center, Seoul, Korea between January 2006 and …

… The gefitinib group included patients treated with gefitinib only … patients who had been
treated with gefitinib prior to erlotinib. The erlotinib group included patients treated with erlotinib …

… Previously treated patients with lung adenocarcinoma were randomly assigned … gefitinib
or erlotinib. This study aimed to investigate the noninferiority of gefitinib compared with erlotinib. …

… We retrospectively reviewed clinical information of patients with ASC who were treated with
gefitinib or erlotinib at Zhejiang Cancer Hospital between January 2007 and December 2011…